Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in ...

Burnaby Hospital’s brand new pavilion will open this year, according to a Burnaby Hospital redevelopment project delegation ...

Landmark exclusive option and license deal with Takeda for ACI-24.060 with $100 million upfront and additional potential milestones of up to about $2.1 billion plus royalties on sales upon ...

The Company is planning to announce interim data from its ongoing Halneuron ® Phase 2b chemotherapy induced neuropathic pain ("CINP”) trial in Q4 2025 ATLANTA, March 13, 2025 (GLOBE NEWSWIRE) -- ...

ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...

Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2024. Cash ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.

Icotrokinra met all primary endpoints in the studies, demonstrating significant skin clearance and clinical remission.

At the Smith County Commissioners Court meeting, Grassroots America raised concerns over delays and budget issues with road ...

Short-term rental operators sued the city of Fort Worth, alleging its ordinance banning Airbnb and VRBO-type rentals was ...

Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after Bristol Myers Squibb BMY agreed to acquire 2seventy bio, Inc TSVT. Meanwhile, other pipeline and ...